Contact Us
Drug Search Results
More Filters [+]

M-3554

Alternative Names: M-3554, M 3554, M3554
Latest Update: None
Latest Update Note: None

Product Description

M3554 is designed a be novel anti-GD2 ADC based on the humanized ch14.18 anti-GD2 antibody. The payload linker consists of the Topoisomerase I inhibitor (TOP1i) payload exatecan and a cleavable beta-glucuronide linker structure, which demonstrated higher potency, better bystander effects and improved activity in multidrug resistant cancer cells compared to other TOP1i payloads. (Sourced from: https://aacrjournals.org/cancerres/article/84/7_Supplement/ND08/742757/Abstract-ND08-M3554-a-novel-anti-GD2-antibody-drug)

Mechanisms of Action: GD2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for M-3554

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions